Information CNX-2006 is a novel irreversible mutant-selectiveEGFRinhibitor withIC50of Targets mutant EGFR In vitro CNX-2006 is a novel irreversible EGFR tyrosine kinase inhibitor, specifically inhibits activating mutations of EGFR as well as the T790M mutation while having very weak inhibition at wild-type EGFR. In in vitro modeling of acquired resistance, continuous CNX-2006 treatment on drug-sensitive EGFR mutant cells leads to resistance more slowly than erlotinib. Dose escalation with CNX-2006 leads to differential effects in different lines, but does not select for T790M-mediated resistance. CNX-2006 resistent cells shows increased expression of EMT markers and MMP9. In vivo CNX-2006 is effective in H1975 (EGFR L858R/T790M) xenograft model. Cell Research(from reference) Cell lines：HEK293 Concentrations：~1000 nM Incubation Time：6 h